Alzamend Neuro
Develops AL001 and ALZN002 candidates for Alzheimer’s disease and psychiatric disorders.
Something off on this page? Send us feedback.
Profile
Develops AL001, a lithium-delivery candidate for Alzheimer’s disease and psychiatric indications, and ALZN002, a patient-specific immunotherapy for Alzheimer’s disease. With no approved products or revenue, progress depends on clinical development, regulatory review, licensing and third-party execution.
Develops two licensed, clinical-stage candidates. AL001 is an ionic cocrystal intended to change lithium delivery for Alzheimer’s disease, bipolar disorder, major depressive disorder and PTSD; ALZN002 is a patient-specific dendritic-cell immunotherapy designed to encourage anti-amyloid immune activity in Alzheimer’s disease.
Operates through an asset-light, U.S.-centered model: core technology is licensed from the University of South Florida Research Foundation, while consultants, contract research organizations and third-party manufacturers support development and supply. AL001 imaging studies compare its delivery profile with lithium carbonate; ALZN002’s trial remains delayed after its CRO ended the engagement.
Has no approved products, product revenue or manufacturing facilities. Commercialization depends on clinical results, regulatory approval, continued license rights and outsourced clinical, manufacturing and trial-execution capacity.
Company facts
Key statistics
Year to date −10.5% · Average volume (30d) 79.1K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 22, 2026Q4 FY26 | −$0.67 | −$0.74 | −10.4% | — | — | — | −6.67% |
| Mar 11, 2026Q3 FY26 | −$0.53 | −$0.58 | −9.4% | — | — | — | −4.13% |
| Dec 9, 2025Q2 FY26 | −$0.83 | −$0.30 | +63.9% | — | — | — | −0.46% |
| Sep 10, 2025Q1 FY26 | −$3.69 | −$1.28 | +65.3% | — | — | — | +2.13% |
Financial highlights
| 12 quarters | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | −$27.7K | |
| Operating income | −$1.0M | −$1.1M | −$2.7M | −$998.1K | −$2.2M | −$2.9M | |
| Net income | −$1.0M | −$1.1M | −$2.7M | −$1.0M | −$2.2M | −$2.9M | |
| Diluted EPS | −$1.70 | −$2.43 | −$1.28 | −$0.30 | −$0.58 | −$0.74 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0 · FY26 $0
Balance sheet, Apr 30, 2026Cash & short-term investments $710.7K · Total debt $0 · Total assets $2.1M · Shareholders' equity $733.2K
Dividends
No dividends on record.
Ownership
Shares outstanding 3.80M · Float —
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Kingsbury Capital Investment Advisors LLC | 566.7K | 14.90% | 13F | Aug 25, 2026 |
| Milton C. Iii Ault · director | 116.6K | 3.07% | Form 4 | Apr 16, 2026 |
| Geode Capital Management, LLC | 45.7K | 1.20% | 13F | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 21.0K | 0.55% | 13F | May 8, 2026 |
| Morgan Stanley | 18.0K | 0.47% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 14, 2026 | Milton C. Iii Ault | director | +108,388 | $1.00 |
| Dec 23, 2025 | Milton C. Iii Ault | director | −1,851 | $2.07 |
| Dec 19, 2025 | William B. Horne | director | −3,333 | $2.12 |
| Oct 23, 2025 | Lynne Fahey McGrath | director | −30 | $2.29 |
| Oct 9, 2025 | Milton C. Iii Ault | director | −20,397 | $2.32 |
Peers
- Eli Lilly
Kisunla leads a large-scale anti-amyloid Alzheimer's challenge.
- Axsome Therapeutics
Auvelity overlaps in MDD and Alzheimer's-dementia symptoms.
- Johnson & Johnson
CAPLYTA and SPRAVATO span bipolar depression and MDD.
- Biogen
Leqembi commercialization brings a scaled anti-amyloid rival.
- AbbVie
VRAYLAR overlaps in bipolar depression and adjunctive MDD.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alzamend Neuro | $1.66 | −2.35% | $6.3M | — | — | — | — |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Axsome Therapeutics | $199.00 | −0.04% | $10.24B | — | 1,707.6 | 13.2 | +44.2% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Median | 39.0 | 22.4 | 7.0 | +10.2% |